Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Fineline Cube Dec 22, 2025
Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Fineline Cube Dec 22, 2025
Company Drug

Immunotech Biopharm’s CAR-T-19-D2 Receives NMPA Approval for DLBCL Clinical Trial

Fineline Cube Mar 22, 2023

China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...

Company Deals

Smith & Nephew Partners with MedMotion for Digital Health Innovation

Fineline Cube Mar 22, 2023

UK-based Smith & Nephew Plc has announced a strategic partnership with China’s Shanghai Fudong Medical...

Company Deals

Aidea Pharma and China Meheco Partner to Expand Medical and Pharmaceutical Services

Fineline Cube Mar 22, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced a partnership with China Meheco...

Company

3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials

Fineline Cube Mar 22, 2023

China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859...

Company Deals

Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000

Fineline Cube Mar 22, 2023

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with...

Company Drug

Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study

Fineline Cube Mar 22, 2023

Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in...

Company Deals

Sinopharm Forms Joint Ventures with Foreign Medical Equipment Firms

Fineline Cube Mar 22, 2023

Sinopharm China National Biotech Group Co., Ltd (CNBG) has announced partnerships with two foreign medical...

Company

BeiGene Marks Topping Off of New Biologics Facility in New Jersey

Fineline Cube Mar 22, 2023

China-based biotech BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) held a ceremony to mark the...

Company Deals Digital

Roche Partners with China Resource Medicine to Promote Xofluza in China

Fineline Cube Mar 22, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has entered into a partnership with China-based China Resource...

Company Deals

Jacobio Pharma Partners with Merck to Evaluate CD73 mAb and Keytruda Combination

Fineline Cube Mar 22, 2023

China-based Jacobio Pharma (HKG: 1167) has announced a clinical partnership with Merck, Sharp & Dohme...

Company Drug

Yifan Pharmaceutical’s F-652 Cleared for Phase II Trial in Alcoholic Hepatitis

Fineline Cube Mar 21, 2023

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary Evive Biotech Ltd’s...

Company Deals

BioNTech Acquires Global Rights to OncoC4’s Anti-CTLA-4 Antibody ONC-392

Fineline Cube Mar 21, 2023

Germany-based mRNA specialist BioNTech SE (NASDAQ: BNTX) has unveiled a licensing deal and collaboration with...

Company Deals

Cygnus Bio Raises Millions in Series C+ Financing for Sequencing Technology

Fineline Cube Mar 21, 2023

Beijing-based second-generation sequencing technology platform Cygnus Bio has reportedly raised “hundreds of millions” of renminbi...

Company Deals

L&L Biopharma Completes Series B Financing for Tumor Immunotherapy Development

Fineline Cube Mar 21, 2023

Shanghai-based tumor immunotherapy developer L&L Biopharma Co., Ltd has announced the completion of a Series...

Company Deals

T&L Biotechnology Secures RMB 100 Million in Series A Financing

Fineline Cube Mar 21, 2023

Beijing-based cell and gene therapy (CGT) developer T&L Biotechnology Co., Ltd has reportedly raised RMB...

Company Drug

Yiling Pharmaceutical’s BIO-008 Receives NMPA Approval for Clinical Trials

Fineline Cube Mar 21, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...

Company Drug

Hengrui Pharmaceuticals’ SHR8028 Receives NMPA Review for Dry Eye Treatment

Fineline Cube Mar 21, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that a market approval filing...

Company Deals

LBX Pharmacy Partners with Gilead Sciences to Enhance Disease Management in China

Fineline Cube Mar 21, 2023

China-based LBX Pharmacy has entered into a partnership with US-based Gilead Sciences, Inc (NASDAQ: GILD)....

Company Drug

Jiangsu Recbio’s ReCOV Vaccine Receives Emergency Use Authorization in Mongolia

Fineline Cube Mar 21, 2023

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced that it has...

Company

WuXi AppTec Reports 71.8% Revenue Growth in 2022 Financials

Fineline Cube Mar 21, 2023

China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) released its 2022 financial report, recording...

Posts pagination

1 … 482 483 484 … 600

Recent updates

  • Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial
  • Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis
  • MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED
  • Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal
  • Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.